Action IMGO IMAGO BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Imago BioSciences, Inc.

Actions

IMGO

US45250K1079

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc
Imago BioSciences : Acquisition/Asset Disposal - Form 8-K
IMAGO BIOSCIENCES, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Imago BioSciences, Inc. Announces Board Changes
Merck & Company Concludes Cash Tender Offer to Acquire Imago BioSciences
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite Index
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P Global BMI Index
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P TMI Index
Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc..
Insider Sell: Imago Biosciences
Insider Sell: Imago Biosciences
Insider Sell: Imago Biosciences
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
Insider Sell: Imago Biosciences
Insider Sell: Imago Biosciences
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Biotechnology Index
Imago BioSciences Reports 'Positive' Mid-Stage Results in Thrombocythemia Trial
IMAGO BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IMGO
  4. Actualités Imago BioSciences, Inc.
  5. Autres langues